August 22, 2012 — A new application of a drug that was approved in 1996 and has been widely used since significantly decreased the frequency of exacerbations and increased the time to first ...

Please provide your email address to receive an email when new articles are posted on . Having a chronic respiratory infection in addition to bronchiectasis heightened the risk for an exacerbation and ...

Highly symptomatic bronchiectasis patients have increased exacerbation risks, regardless of previous exacerbation history or disease severity. Current guidelines do not recommend preventive treatments ...

Please provide your email address to receive an email when new articles are posted on . The relationship between blood eosinophil count and bronchiectasis severity was U-shaped, meaning greater ...

Panelists discuss how bacterial infections, environmental triggers, and microbiome imbalances cause bronchiectasis exacerbations, leading to increased cough, phlegm, fatigue, and hemoptysis.

Prior exacerbations and greater symptom severity independently predicted future exacerbations in patients with bronchiectasis. Long-term macrolide proved beneficial not only for patients with frequent ...

Insmed plans to file a New Drug Application with the Food and Drug Administration in the fourth quarter of 2024. Treatment with brensocatib reduced the frequency of pulmonary exacerbations in patients ...

The ASPEN randomized trial showed that novel brensocatib cut the annualized rate of pulmonary exacerbations by around 20% compared with placebo. Brensocatib is a DPP-1 inhibitor that works by reducing ...

Bronchiectasis is one of the most common highly heterogeneous chronic inflammatory airway diseases in China. It has a long course, heavy symptom burden, and is prone to recurrent acute exacerbations, ...

Insmed To Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results From Phase 3B ENCORE Study, At The American Thoracic Society International Conference 2026. -New Data ...

The American Thoracic Society (ATS) today announced a major quality improvement initiative aimed at tackling the persistent ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...